According to some market research reports overall antibiotic market is projected to have sales worth $65.5 Billion by year 2014 and is projected to have annual growth rate of 9.6%. In Indian scenario we have many companies to look forth who have in recent years transformed themselves from being chemistry based generic company to Biopharmaceutical vaccine based companies.
This Wednesday Daichii's Indian subsidiary Ranbaxy announced that it has acquired BioVel a Bangalore based Vaccine development company, with this deal Ranbaxy gets access to Biovel's patent, product portfolio, its expertise in vaccine domain and Ranbaxy will have access to it's WHO-certified pilot plant for pre-filled syringes in Bangalore
For more information on Biovel you can read in
http://www.blonnet.com/2010/01/20/stories/2010012052160200.htm
No comments:
Post a Comment